Smoking cessation treatment outcomes among people with and without mental and substance use disorders: An observational real-world study
There is a lack of studies evaluating smoking cessation treatment protocols which include people with and without mental and substance use disorders (MSUD), and which allows for individuals with MSUD undergoing their psychiatric treatment. We compared treatment success between participants with (n =...
Gespeichert in:
Veröffentlicht in: | European psychiatry 2018-08, Vol.52, p.22-28 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 28 |
---|---|
container_issue | |
container_start_page | 22 |
container_title | European psychiatry |
container_volume | 52 |
creator | Castaldelli-Maia, João Mauricio Loreto, Aline Rodrigues Guimarães-Pereira, Bruna Beatriz Sales Carvalho, Carlos Felipe Cavalcanti Gil, Felipe Frallonardo, Fernanda Piotto Ismael, Flávia Andrade, Arthur Guerra de Ventriglio, Antonio Richter, Kimber P. Bhugra, Dinesh |
description | There is a lack of studies evaluating smoking cessation treatment protocols which include people with and without mental and substance use disorders (MSUD), and which allows for individuals with MSUD undergoing their psychiatric treatment.
We compared treatment success between participants with (n = 277) and without (n = 419) MSUD among patients in a 6-week treatment provided by a Brazilian Psychosocial Care Center (CAPS) from 2007 to 2013. Sociodemographic, medical and tobacco use characteristics were assessed at baseline. Tobacco treatment consisted of 1) group cognitive behavior therapy, which included people with and without MSUD in the same groups, and 2) pharmacotherapy, which could include either nicotine patches, nicotine gum, bupropion or nortriptyline. For participants with MSUD, tobacco treatment was integrated into their ongoing mental health treatment. The main outcome was 30-day point prevalence abstinence, measured at last day of treatment.
Abstinence rates did not differ significantly between participants with and without MSUD (31.1% and 34.4%, respectively). Variables that were significantly associated with treatment success included years smoking, the Heaviness of Smoking Index, and use of nicotine patch or bupropion.
The inclusion of individuals with and without MSUD in the same protocol, allowing for individuals with MSUD undergoing their psychiatric treatment, generates at least comparable success rates between the groups. Predictors of treatment success were similar to those found in the general population. Facilities that treat patients with MSUD should treat tobacco use in order to reduce the disparities in morbidity and mortality experienced by this population. |
doi_str_mv | 10.1016/j.eurpsy.2018.02.005 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2021318857</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S092493381830066X</els_id><sourcerecordid>2021318857</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-443bcec182cf60907f292e23aa849c8d1017b4dd9e27952d78af5ea2202655233</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhS0EokPhDarKSzYJthMnThdI1aj8SJVYAGvLsW-op0kcfJ1W8wY8Np6ZliUrX1nfuUf3HEIuOCs5482HXQlrXHBfCsZVyUTJmHxBNrxtVVFJJV-SDetEXXRVpc7IG8QdY7xlrHlNzkTXsI7JZkP-fJ_CvZ9_UQuIJvkw0xTBpAnmRMOabJgAqZlCRhYIywj00ac7amZ3HDJCD6wZj1-49pjMbIGuCNR5DNFBxCt6PdPQI8SHo0ems8lYPIY4ZlFa3f4teTWYEeHd03tOfn66-bH9Utx--_x1e31b2JqpVNR11VuwXAk7HG5oB9EJEJUxqu6scjmatq-d60C0nRSuVWaQYIRgopFSVNU5eX_au8TwewVMevJoYRzNDGFFnUFecaVkm9H6hNoYECMMeol-MnGvOdOHDvROnzrQhw40Ezp3kGWXTw5rP4H7J3oOPQMfTwDkOx88RI3WQw7N-Qg2aRf8_x3-AsQPnS4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2021318857</pqid></control><display><type>article</type><title>Smoking cessation treatment outcomes among people with and without mental and substance use disorders: An observational real-world study</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Castaldelli-Maia, João Mauricio ; Loreto, Aline Rodrigues ; Guimarães-Pereira, Bruna Beatriz Sales ; Carvalho, Carlos Felipe Cavalcanti ; Gil, Felipe ; Frallonardo, Fernanda Piotto ; Ismael, Flávia ; Andrade, Arthur Guerra de ; Ventriglio, Antonio ; Richter, Kimber P. ; Bhugra, Dinesh</creator><creatorcontrib>Castaldelli-Maia, João Mauricio ; Loreto, Aline Rodrigues ; Guimarães-Pereira, Bruna Beatriz Sales ; Carvalho, Carlos Felipe Cavalcanti ; Gil, Felipe ; Frallonardo, Fernanda Piotto ; Ismael, Flávia ; Andrade, Arthur Guerra de ; Ventriglio, Antonio ; Richter, Kimber P. ; Bhugra, Dinesh</creatorcontrib><description>There is a lack of studies evaluating smoking cessation treatment protocols which include people with and without mental and substance use disorders (MSUD), and which allows for individuals with MSUD undergoing their psychiatric treatment.
We compared treatment success between participants with (n = 277) and without (n = 419) MSUD among patients in a 6-week treatment provided by a Brazilian Psychosocial Care Center (CAPS) from 2007 to 2013. Sociodemographic, medical and tobacco use characteristics were assessed at baseline. Tobacco treatment consisted of 1) group cognitive behavior therapy, which included people with and without MSUD in the same groups, and 2) pharmacotherapy, which could include either nicotine patches, nicotine gum, bupropion or nortriptyline. For participants with MSUD, tobacco treatment was integrated into their ongoing mental health treatment. The main outcome was 30-day point prevalence abstinence, measured at last day of treatment.
Abstinence rates did not differ significantly between participants with and without MSUD (31.1% and 34.4%, respectively). Variables that were significantly associated with treatment success included years smoking, the Heaviness of Smoking Index, and use of nicotine patch or bupropion.
The inclusion of individuals with and without MSUD in the same protocol, allowing for individuals with MSUD undergoing their psychiatric treatment, generates at least comparable success rates between the groups. Predictors of treatment success were similar to those found in the general population. Facilities that treat patients with MSUD should treat tobacco use in order to reduce the disparities in morbidity and mortality experienced by this population.</description><identifier>ISSN: 0924-9338</identifier><identifier>EISSN: 1778-3585</identifier><identifier>DOI: 10.1016/j.eurpsy.2018.02.005</identifier><identifier>PMID: 29609056</identifier><language>eng</language><publisher>England: Elsevier Masson SAS</publisher><subject>Adult ; Brazil ; Bupropion - therapeutic use ; Cognitive Behavioral Therapy - methods ; Combined Modality Therapy ; Comorbidity ; Female ; Humans ; Male ; Mental Disorders - complications ; Mental Disorders - psychology ; Mental health ; Middle Aged ; Nicotine - therapeutic use ; Nortriptyline - therapeutic use ; Outcome and Process Assessment, Health Care ; Psychotherapy, Group - methods ; Smoking ; Smoking - psychology ; Smoking Cessation - psychology ; Substance use disorders ; Substance-Related Disorders - complications ; Substance-Related Disorders - psychology ; Tobacco ; Treatment ; Treatment Outcome</subject><ispartof>European psychiatry, 2018-08, Vol.52, p.22-28</ispartof><rights>2018 Elsevier Masson SAS</rights><rights>Copyright © 2018 Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-443bcec182cf60907f292e23aa849c8d1017b4dd9e27952d78af5ea2202655233</citedby><cites>FETCH-LOGICAL-c408t-443bcec182cf60907f292e23aa849c8d1017b4dd9e27952d78af5ea2202655233</cites><orcidid>0000-0001-9621-2291</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,27931,27932</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29609056$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Castaldelli-Maia, João Mauricio</creatorcontrib><creatorcontrib>Loreto, Aline Rodrigues</creatorcontrib><creatorcontrib>Guimarães-Pereira, Bruna Beatriz Sales</creatorcontrib><creatorcontrib>Carvalho, Carlos Felipe Cavalcanti</creatorcontrib><creatorcontrib>Gil, Felipe</creatorcontrib><creatorcontrib>Frallonardo, Fernanda Piotto</creatorcontrib><creatorcontrib>Ismael, Flávia</creatorcontrib><creatorcontrib>Andrade, Arthur Guerra de</creatorcontrib><creatorcontrib>Ventriglio, Antonio</creatorcontrib><creatorcontrib>Richter, Kimber P.</creatorcontrib><creatorcontrib>Bhugra, Dinesh</creatorcontrib><title>Smoking cessation treatment outcomes among people with and without mental and substance use disorders: An observational real-world study</title><title>European psychiatry</title><addtitle>Eur Psychiatry</addtitle><description>There is a lack of studies evaluating smoking cessation treatment protocols which include people with and without mental and substance use disorders (MSUD), and which allows for individuals with MSUD undergoing their psychiatric treatment.
We compared treatment success between participants with (n = 277) and without (n = 419) MSUD among patients in a 6-week treatment provided by a Brazilian Psychosocial Care Center (CAPS) from 2007 to 2013. Sociodemographic, medical and tobacco use characteristics were assessed at baseline. Tobacco treatment consisted of 1) group cognitive behavior therapy, which included people with and without MSUD in the same groups, and 2) pharmacotherapy, which could include either nicotine patches, nicotine gum, bupropion or nortriptyline. For participants with MSUD, tobacco treatment was integrated into their ongoing mental health treatment. The main outcome was 30-day point prevalence abstinence, measured at last day of treatment.
Abstinence rates did not differ significantly between participants with and without MSUD (31.1% and 34.4%, respectively). Variables that were significantly associated with treatment success included years smoking, the Heaviness of Smoking Index, and use of nicotine patch or bupropion.
The inclusion of individuals with and without MSUD in the same protocol, allowing for individuals with MSUD undergoing their psychiatric treatment, generates at least comparable success rates between the groups. Predictors of treatment success were similar to those found in the general population. Facilities that treat patients with MSUD should treat tobacco use in order to reduce the disparities in morbidity and mortality experienced by this population.</description><subject>Adult</subject><subject>Brazil</subject><subject>Bupropion - therapeutic use</subject><subject>Cognitive Behavioral Therapy - methods</subject><subject>Combined Modality Therapy</subject><subject>Comorbidity</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Mental Disorders - complications</subject><subject>Mental Disorders - psychology</subject><subject>Mental health</subject><subject>Middle Aged</subject><subject>Nicotine - therapeutic use</subject><subject>Nortriptyline - therapeutic use</subject><subject>Outcome and Process Assessment, Health Care</subject><subject>Psychotherapy, Group - methods</subject><subject>Smoking</subject><subject>Smoking - psychology</subject><subject>Smoking Cessation - psychology</subject><subject>Substance use disorders</subject><subject>Substance-Related Disorders - complications</subject><subject>Substance-Related Disorders - psychology</subject><subject>Tobacco</subject><subject>Treatment</subject><subject>Treatment Outcome</subject><issn>0924-9338</issn><issn>1778-3585</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1u1DAUhS0EokPhDarKSzYJthMnThdI1aj8SJVYAGvLsW-op0kcfJ1W8wY8Np6ZliUrX1nfuUf3HEIuOCs5482HXQlrXHBfCsZVyUTJmHxBNrxtVVFJJV-SDetEXXRVpc7IG8QdY7xlrHlNzkTXsI7JZkP-fJ_CvZ9_UQuIJvkw0xTBpAnmRMOabJgAqZlCRhYIywj00ac7amZ3HDJCD6wZj1-49pjMbIGuCNR5DNFBxCt6PdPQI8SHo0ems8lYPIY4ZlFa3f4teTWYEeHd03tOfn66-bH9Utx--_x1e31b2JqpVNR11VuwXAk7HG5oB9EJEJUxqu6scjmatq-d60C0nRSuVWaQYIRgopFSVNU5eX_au8TwewVMevJoYRzNDGFFnUFecaVkm9H6hNoYECMMeol-MnGvOdOHDvROnzrQhw40Ezp3kGWXTw5rP4H7J3oOPQMfTwDkOx88RI3WQw7N-Qg2aRf8_x3-AsQPnS4</recordid><startdate>201808</startdate><enddate>201808</enddate><creator>Castaldelli-Maia, João Mauricio</creator><creator>Loreto, Aline Rodrigues</creator><creator>Guimarães-Pereira, Bruna Beatriz Sales</creator><creator>Carvalho, Carlos Felipe Cavalcanti</creator><creator>Gil, Felipe</creator><creator>Frallonardo, Fernanda Piotto</creator><creator>Ismael, Flávia</creator><creator>Andrade, Arthur Guerra de</creator><creator>Ventriglio, Antonio</creator><creator>Richter, Kimber P.</creator><creator>Bhugra, Dinesh</creator><general>Elsevier Masson SAS</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9621-2291</orcidid></search><sort><creationdate>201808</creationdate><title>Smoking cessation treatment outcomes among people with and without mental and substance use disorders: An observational real-world study</title><author>Castaldelli-Maia, João Mauricio ; Loreto, Aline Rodrigues ; Guimarães-Pereira, Bruna Beatriz Sales ; Carvalho, Carlos Felipe Cavalcanti ; Gil, Felipe ; Frallonardo, Fernanda Piotto ; Ismael, Flávia ; Andrade, Arthur Guerra de ; Ventriglio, Antonio ; Richter, Kimber P. ; Bhugra, Dinesh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-443bcec182cf60907f292e23aa849c8d1017b4dd9e27952d78af5ea2202655233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult</topic><topic>Brazil</topic><topic>Bupropion - therapeutic use</topic><topic>Cognitive Behavioral Therapy - methods</topic><topic>Combined Modality Therapy</topic><topic>Comorbidity</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Mental Disorders - complications</topic><topic>Mental Disorders - psychology</topic><topic>Mental health</topic><topic>Middle Aged</topic><topic>Nicotine - therapeutic use</topic><topic>Nortriptyline - therapeutic use</topic><topic>Outcome and Process Assessment, Health Care</topic><topic>Psychotherapy, Group - methods</topic><topic>Smoking</topic><topic>Smoking - psychology</topic><topic>Smoking Cessation - psychology</topic><topic>Substance use disorders</topic><topic>Substance-Related Disorders - complications</topic><topic>Substance-Related Disorders - psychology</topic><topic>Tobacco</topic><topic>Treatment</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Castaldelli-Maia, João Mauricio</creatorcontrib><creatorcontrib>Loreto, Aline Rodrigues</creatorcontrib><creatorcontrib>Guimarães-Pereira, Bruna Beatriz Sales</creatorcontrib><creatorcontrib>Carvalho, Carlos Felipe Cavalcanti</creatorcontrib><creatorcontrib>Gil, Felipe</creatorcontrib><creatorcontrib>Frallonardo, Fernanda Piotto</creatorcontrib><creatorcontrib>Ismael, Flávia</creatorcontrib><creatorcontrib>Andrade, Arthur Guerra de</creatorcontrib><creatorcontrib>Ventriglio, Antonio</creatorcontrib><creatorcontrib>Richter, Kimber P.</creatorcontrib><creatorcontrib>Bhugra, Dinesh</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Castaldelli-Maia, João Mauricio</au><au>Loreto, Aline Rodrigues</au><au>Guimarães-Pereira, Bruna Beatriz Sales</au><au>Carvalho, Carlos Felipe Cavalcanti</au><au>Gil, Felipe</au><au>Frallonardo, Fernanda Piotto</au><au>Ismael, Flávia</au><au>Andrade, Arthur Guerra de</au><au>Ventriglio, Antonio</au><au>Richter, Kimber P.</au><au>Bhugra, Dinesh</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Smoking cessation treatment outcomes among people with and without mental and substance use disorders: An observational real-world study</atitle><jtitle>European psychiatry</jtitle><addtitle>Eur Psychiatry</addtitle><date>2018-08</date><risdate>2018</risdate><volume>52</volume><spage>22</spage><epage>28</epage><pages>22-28</pages><issn>0924-9338</issn><eissn>1778-3585</eissn><abstract>There is a lack of studies evaluating smoking cessation treatment protocols which include people with and without mental and substance use disorders (MSUD), and which allows for individuals with MSUD undergoing their psychiatric treatment.
We compared treatment success between participants with (n = 277) and without (n = 419) MSUD among patients in a 6-week treatment provided by a Brazilian Psychosocial Care Center (CAPS) from 2007 to 2013. Sociodemographic, medical and tobacco use characteristics were assessed at baseline. Tobacco treatment consisted of 1) group cognitive behavior therapy, which included people with and without MSUD in the same groups, and 2) pharmacotherapy, which could include either nicotine patches, nicotine gum, bupropion or nortriptyline. For participants with MSUD, tobacco treatment was integrated into their ongoing mental health treatment. The main outcome was 30-day point prevalence abstinence, measured at last day of treatment.
Abstinence rates did not differ significantly between participants with and without MSUD (31.1% and 34.4%, respectively). Variables that were significantly associated with treatment success included years smoking, the Heaviness of Smoking Index, and use of nicotine patch or bupropion.
The inclusion of individuals with and without MSUD in the same protocol, allowing for individuals with MSUD undergoing their psychiatric treatment, generates at least comparable success rates between the groups. Predictors of treatment success were similar to those found in the general population. Facilities that treat patients with MSUD should treat tobacco use in order to reduce the disparities in morbidity and mortality experienced by this population.</abstract><cop>England</cop><pub>Elsevier Masson SAS</pub><pmid>29609056</pmid><doi>10.1016/j.eurpsy.2018.02.005</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-9621-2291</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0924-9338 |
ispartof | European psychiatry, 2018-08, Vol.52, p.22-28 |
issn | 0924-9338 1778-3585 |
language | eng |
recordid | cdi_proquest_miscellaneous_2021318857 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
subjects | Adult Brazil Bupropion - therapeutic use Cognitive Behavioral Therapy - methods Combined Modality Therapy Comorbidity Female Humans Male Mental Disorders - complications Mental Disorders - psychology Mental health Middle Aged Nicotine - therapeutic use Nortriptyline - therapeutic use Outcome and Process Assessment, Health Care Psychotherapy, Group - methods Smoking Smoking - psychology Smoking Cessation - psychology Substance use disorders Substance-Related Disorders - complications Substance-Related Disorders - psychology Tobacco Treatment Treatment Outcome |
title | Smoking cessation treatment outcomes among people with and without mental and substance use disorders: An observational real-world study |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T23%3A11%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Smoking%20cessation%20treatment%20outcomes%20among%20people%20with%20and%20without%20mental%20and%20substance%20use%20disorders:%20An%20observational%20real-world%20study&rft.jtitle=European%20psychiatry&rft.au=Castaldelli-Maia,%20Jo%C3%A3o%20Mauricio&rft.date=2018-08&rft.volume=52&rft.spage=22&rft.epage=28&rft.pages=22-28&rft.issn=0924-9338&rft.eissn=1778-3585&rft_id=info:doi/10.1016/j.eurpsy.2018.02.005&rft_dat=%3Cproquest_cross%3E2021318857%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2021318857&rft_id=info:pmid/29609056&rft_els_id=S092493381830066X&rfr_iscdi=true |